Physician profile
Robert E Reif
NPI 1558406231
$32,521.23
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,763 · 2020: $13K · 2021: $14K · 2022: $3,086 · 2023: $149 · 2024: $23.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13,562.35 | 2020-2021 | |
| Abbvie INC. | $7,000.62 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $1,974.99 | 2019-2024 | |
| Biogen, INC. | $1,323.90 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,251.15 | 2019-2022 | |
| Livanova USA, INC. | $725.04 | 2019-2021 | |
| Amgen INC. | $588.25 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $523.58 | 2019-2022 | |
| Genzyme Corporation | $466.54 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $433.05 | 2019-2021 | |
| Harmony Biosciences LLC | $361.96 | 2020-2022 | |
| Grifols USA, LLC | $342.32 | 2019-2022 | |
| Ucb, INC. | $332.95 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $223.72 | 2021 | |
| Eisai INC. | $223.71 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.